Skip to content

Evaluation of a novel Valsalva Assist Device for terminating supraventricular tachycardia: a randomized controlled trial

Evaluation of a novel Valsalva Assist Device for terminating supraventricular tachycardia: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113995
Enrollment
Unknown
Registered
2025-12-05
Start date
2022-03-16
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Supraventricular tachycardia

Interventions

A:Valsalva Assist Device
B:Standard Valsalva manoeuvre

Sponsors

Capital Medical University affiliated Beijing Anzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age between 16 and 80 years 2.Patient having SVT with regular, narrow complex tachy-arrythmia with a QRS duration < 0.12 ms on ECG and eligible for treatment with the VM.

Exclusion criteria

Exclusion criteria: 1.Unable or unwilling to give informed verbal consent. 2.SVT episode with hemodynamic instability (systolic blood pressure (BP) 220 mmHg or diastolic BP > 120 mmHg). 5.Contraindication or inability to perform a VM (aortic stenosis, recent myocardial infarction, glaucoma, retinopathy, recent eye surgery, paralysis). 6.Third trimester pregnancy. 7.Previous catheter ablation of SVT.

Design outcomes

Secondary

MeasureTime frame
Presence of sinus rhythm at 1min after once VM;

Primary

MeasureTime frame
Presence of sinus rhythm at 1min after twice VM;

Countries

China

Contacts

Public ContactLi Songnan

Capital Medical University affiliated Beijing Anzhen Hospital

lisongnan@ccmu.edu.cn+86 136 7134 6119

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026